Global Infertility Services Market Strategic Research Report

Scope of the Report

The global Infertility Services market size is predicted to grow from US$ 8,449 million in 2025 to US$ 13,710 million in 2032; it is expected to grow at a CAGR of 7.2% from 2026 to 2032.

Infertility services refer to medical procedures and treatments that are designed to help individuals or couples who are experiencing difficulties in conceiving a child. These services aim to diagnose and treat the underlying causes of infertility, and potentially assist in achieving a successful pregnancy.

Infertility services have become an important part of the global medical field in recent years. With the change of lifestyle, the influence of environmental factors and the change of fertility concepts, infertility has gradually become an important social and health issue worldwide. According to statistics from the World Health Organization (WHO), about 10-15% of couples in the world face infertility problems. This proportion varies in different countries and regions, but the prevalence of this problem has prompted the rapid development of the infertility treatment market.

At present, the scale of the infertility service market is growing globally and is expected to continue to grow in the next few years. The rapid development of assisted reproductive technology (ART) has given hope to many couples who were once unable to get pregnant. The maturity of technologies such as in vitro fertilization (IVF), egg freezing, intracytoplasmic sperm injection (ICSI), and embryo genetic screening (PGS/PGD) has not only increased the success rate, but also allowed more infertile patients to enjoy treatment. In addition, with the advancement of genetic testing technology, the popularization of preimplantation genetic screening can effectively reduce the risk of chromosomal abnormalities and increase the chance of successful pregnancy.

Despite the rapid growth of the infertility service market, it still faces some challenges and problems:

High treatment costs: Assisted reproductive technologies such as IVF are expensive and not all families can afford them. Especially in some developing countries or regions, although the technology is gradually becoming popular, the cost of treatment is still a major obstacle. Therefore, how to reduce treatment costs and provide more economical treatment options is still a difficult problem that needs to be solved. Differences in technology accessibility: Although some advanced assisted reproductive technologies have been popularized in some developed countries, in many developing countries and regions, these technologies are not yet popular and the accessibility of treatment is low. In addition, the imbalance of medical facilities has caused a gap in the treatment of infertility in patients in different regions and industries.

With the continuous advancement of science and technology and the increase in social needs, the future development trend of the infertility service market is becoming clearer and clearer.

The core manufacturers of global infertility services include Ferring Pharmaceuticals, Merck, Jinxin Fertility, Vitrolife, Mayo Clinic and LIVZON. The top three manufacturers account for approximately 24% of the global share. The Asia-Pacific region is the world's largest market, accounting for nearly 45% of the market share.

In terms of product type, assisted reproductive technology (ART) occupies a dominant position, accounting for 62% of the market share. At the same time, in terms of application, females are the largest application field, accounting for 66%.

This report presents a comprehensive overview of the global Infertility Services market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Assisted Reproductive Technology (ART)
• Infertility Drug Services
• Others

Segment by players, this report covers

• Ferring Pharmaceuticals
• Merck
• Jinxin Fertility
• Vitrolife
• Mayo Clinic
• LIVZON
• Abbott
• Monash IVF
• CARE Facility
• Theramex
• TriHealth
• NMC Health
• CooperSurgical
• Irvine Scientific
• Virtus Health
• CinnaGen
• OB GYN Associates
• Caerus Biotech
• InVitroCare
• INVO Bioscience

Segment by Application

• Male
• Female

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Infertility Services market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Male, Female evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact